The generic industry should have a better indication Aug. 9 of where FDA stands and could go on the subject of tablet scoring.
Members of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology will consider a number of potential tablet coring requirements...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?